AbbVie Inc (ABBV) Stock Forecast
US · Healthcare
Current price
$243.14
Market cap
$429.58B
Mean price target
$254.38
Implied upside
4.6%
Key takeaways
- Analysts rate AbbVie Inc a “Buy”, with a mean price target of $254.38 — about 4.6% upside from the current $243.14, based on 29 analysts.
- ABBV is trading near its 52-week high, at 97% of the $181.73–$244.81 band.
Analyst consensus
| Consensus rating | Buy |
|---|---|
| Number of analysts | 29 |
| Mean target | $254.38 |
| High target | $328.00 |
| Low target | $200.00 |
| Rating split (SB / B / H / S / SS) | 8 / 14 / 9 / 0 / 0 |
Price & trading
| Current price | $243.14 |
|---|---|
| Previous close | $234.89 |
| 52-week high | $244.81 |
| 52-week low | $181.73 |
| 50-day average | $213.23 |
| Beta | 0.31 |
See the full ABBV breakdown on Luminoso
Valuation, profitability, efficiency, leverage & earnings-quality metrics — updated daily.
Start free — 2 months on usFrequently asked questions
- What is the current AbbVie Inc (ABBV) share price?
- AbbVie Inc last traded at $243.14 with a market capitalisation of about $429.6B.
- What is the analyst price target for ABBV?
- The mean analyst price target for AbbVie Inc is $254.38, roughly 4.6% above the latest price. The current consensus rating is “Buy”.
- Where can I see AbbVie Inc's full financial metrics?
- Luminoso tracks ABBV's valuation, profitability, efficiency, leverage and earnings-quality metrics alongside analyst data — updated daily. Create a free account to explore the full breakdown.
More stocks
Browse all companies covered by Luminoso →
Last updated 25 Jun 2026.
Data is provided for informational purposes only and is not investment advice. Figures are cached and refreshed daily; they may differ from real-time quotes.